Objective: To assess the correlation between standard laboratory indicators at admission and severe maternal complications due to placental abruption (PA) with intrauterine fetal death (IUFD) after 24 weeks.Methods: Retrospective study in three French tertiary referral hospitals. Correlation of laboratory indicators at admission (platelet count, prothrombin, activated partial thromboplastin time, fibrinogen) and severe maternal complications (massive transfusion, multiple organ failure, hysterectomy, or maternal deaths) in patients with PA and IUFD.Results: Over 12 years, we identified 27/344 (7.8%) pregnant women presenting PA with IUFD. No patient had coagulopathy at admission. Fifteen individuals (55.5%) underwent delivery by cesarean section before or during labor. Fifteen individuals (55.5%) presented severe complications, and 17/27 (63%) lost more than 1 L of blood during delivery. Fibrinogen level was shown to be the laboratory indicator most correlated with severe complications (r = −0.52, P = 0.01). The receiver operating characteristic curve of fibrinogen less than 1.9 g/L in the prediction of severe complications (area under the curve = 0.80, 95% confidence interval [CI] 0.54–0.97) showed both a sensitivity and specificity of 83% (95% CI 54%–96%).Conclusions: In cases of IUFD with PA, fibrinogen levels at admission had a prognostic value for the prediction of severe maternal complications.
Fetal Growth restriction (FGR) is the pathological failure of a fetus to reach its biologically determined growth potential. Detection of FGR fetuses is a universally agreed key objective of antena...
The epidemiology of Toxoplasma infection is known to vary geographically, but is also likely to vary over time, under the influence of many contributing factors. Monitoring is particularly useful in the context of preventing congenital toxoplasmosis. We took advantage of the French prenatal prevention programme to retrospectively assess changes between 2017 and 2023 in seroprevalence and incidence rates of Toxoplasma infection in pregnant women and the incidence of congenital infections. We conducted a longitudinal retrospective study including all pregnancies with known Toxoplasma status followed up at Lyon’s public maternity hospitals between 2017 and 2023 (71,922 pregnancies). We used a multivariable logistic regression model to identify factors (age-group, WHO region of origin, population density of the area of residence and parity) associated with seropositivity. The seroprevalence of toxoplasmosis decreased consistently from 26.4% in 2017 to 22.1% in 2023 (p = 0.003), while maternal infection incidence remained stable at 1.3/1,000 pregnancies at risk. Notably, the seroprevalence showed a linear increase with age from 18.9% in women aged 25–29 years to 38.0% in women aged ≥40 years (p < 0.001). The seroprevalence was lower in pregnant women living in rural areas [adjusted seroprevalence ratio (aPR) = 0.87, 95% CI: 0.82–0.92] and higher in multiparous women (aPR = 1.08, 95% CI: 1.04–1.12). This study confirms the ongoing decline in toxoplasmosis seroprevalence while seroconversions remained stable, indicating a need for more tests in seronegative women in the future. These findings highlight the need for ongoing monitoring and refinement of congenital toxoplasmosis prevention strategies in high-income countries.
The pathophysiology of preeclampsia and HELLP syndrome relies on systemic vascular endothelial dysfunction, resulting from angiogenic imbalance due to abnormal uteroplacental vascular remodeling and placental ischemia/reperfusion. Recent studies demonstrated that HELLP syndrome falls within the spectrum of secondary microangiopathy due to abnormal complement activation. However, to date, the link between angiogenic imbalance, endothelial dysfunction, and complement activation remains unclear. Building upon current understanding of complement regulation, this paper proposes a novel pathophysiological approach, suggesting a new understanding of HELLP syndrome and preeclampsia, including the undebatable role of sFlt‐1/PlGF and the knowledge of maternal systemic endothelial and renal diseases. We hypothesize that endothelial glycocalyx may be the missing link between angiogenic factors, inflammatory regulation, and endothelial maternal lesions. Targeting the glycocalyx‐endothelium axis may enable novel therapeutic strategies that delay delivery and reduce maternal‐neonatal morbidity in preeclampsia and HELLP syndrome.